NCT03729492

Brief Summary

Aim: To investigate if a symptom driven referral for chronic thrombosis in the lungs after acute pulmonary embolism is better than the current approach. Background: A number of patients with chronic thrombosis in the lungs after acute pulmonary embolism have dyspnea and reduced functional capacity without elevated pulmonary arterial pressure at rest (CTED). However, current guidelines for follow-up after acute pulmonary embolism will miss all patients with CTED, as referral for further examination is based on elevated pulmonary arterial pressure on echocardiography. Thus, the prevalence of CTED is unknown. The hypothesis is, that a symptom-driven referral of patients with previous acute pulmonary embolism is more sensitive in diagnosing CTED than the current approach. Methods and materials: Patients diagnosed with acute pulmonary embolism in Region Midt (approx. 350 per year) will be screened for non-recovery or persistent pulmonary embolism related symptoms during their 3-6 months follow up at their local outpatient clinic. If the patient has persistent symptoms they will be referred to a scintigraphy. If CTED is suspected from the scintigraphy, the patient will be referred for full CTED work-up. The investigators expect to screen 300 patients for persistent symptoms with an expected study time of 3 years.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2019

Longer than P75 for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 1, 2018

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 2, 2018

Completed
3 months until next milestone

Study Start

First participant enrolled

February 1, 2019

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2022

Completed
Last Updated

November 2, 2018

Status Verified

October 1, 2018

Enrollment Period

3.8 years

First QC Date

November 1, 2018

Last Update Submit

November 1, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Prevalence of CTED

    3 years

Secondary Outcomes (1)

  • Diagnostic accuracy of dual energy CT perfusion and pulmonary angiography.

    3 years

Study Arms (1)

CTEPH/CTED work-up

OTHER
Diagnostic Test: CTEPH/CTED work-up

Interventions

CTEPH/CTED work-upDIAGNOSTIC_TEST

Patients diagnosed with acute pulmonary embolism (PE) in Region Midt (approx. 350 per year) will be screened for non-recovery or persistent PE related symptoms during their 3-6 months follow up at their local outpatient clinic. If the patient has persistent symptoms they will be referred to a V/Q-scan. If a V/Q mismatch is present, the patient will be referred to a full work-up for CTEPH/CTED.

CTEPH/CTED work-up

Eligibility Criteria

Age18 Years - 79 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Acute PE diagnosed by CT or V/Q-scan within the last year.
  • Non-recovery or persistent PE related symptoms assessed by a MRC breathlessness score or WHO functional class.
  • Age \>= 18 and \< 80

You may not qualify if:

  • Contraindications or unable to perform 6 minutes walk distance (6MWD) and/or cardiopulmonary exercise test.
  • Contraindications to CT pulmonary angiography.
  • Congestive heart failure (LVEF \<40%).
  • COPD or restrictive lung disease, severe or worse (FEV1 \<50% and \>=1 exacerbation causing hospital admission per year (GOLD grade 3 and 4 class C and D)).
  • Lactating or pregnant.
  • Unable or unwilling to provide written informed consent.
  • Paroxysmal or persistent atrial fibrillation.
  • Other known cause of PE related symptoms.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Asger Andersen, MD, PhD

    Aarhus University Hospital

    STUDY CHAIR

Central Study Contacts

Mona S Hansen, MD

CONTACT

Asger Andersen, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 1, 2018

First Posted

November 2, 2018

Study Start

February 1, 2019

Primary Completion

November 1, 2022

Study Completion

November 1, 2022

Last Updated

November 2, 2018

Record last verified: 2018-10

Data Sharing

IPD Sharing
Will not share